An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.
Read Article
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read Article
Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.
A cohort of 106 cSLE (93% female, 73% White
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
Read Article
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do
Read Article
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read Article
Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health. These patients were previously misdiagnosed with Sweets syndrome, relapsing polychondritis, myelodysplastic syndrome, MGUS, or polyarteritis
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Does uric acid contribute to the risk of hypertension (HTN)? A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).
Previous research in a small cohort of obese hypertensive kids showed that urate lowering therapy was assoaciated
Read Article
Dr. John Cush @RheumNow( View Tweet )
Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that
Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Olga Petryna @DrPetryna( View Tweet )
A multicentre, retrospective study examined MSA profiles (by immunoprecipitation) from 96 juvenile idiopathic inflammatory myopathies (JIIM) at nine pediatric rheumatology centres in Japan. MSA were found in 85 of 96 cases with over 90% of patients having one of the following three MSA types
Read Article
There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.
The early data
Read Article
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Read Article
Links:
Links:
A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).
Read Article
